Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.

Gupta, G; Dahiya, R; Singh, Y; Mishra, A; Verma, A; Gothwal, SK; Aljabali, AAA; Dureja, H; Prasher, P; Negi, P; Kapoor, DN; Goyal, R; Tambuwala, MM; Chellappan, DK; Dua, K

Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.

Gupta, G Dahiya, R Singh, Y Mishra, A Verma, A Gothwal, SK Aljabali, AAA Dureja, H Prasher, P Negi, P Kapoor, DN Goyal, R Tambuwala, MM Chellappan, DK Dua, K

Permalink

Publisher:: ELSEVIER IRELAND LTD
Publication Type:: Journal Article
Citation:: Chemico-biological interactions, 2020, 317
Issue Date:: 2020-02-04

Closed Access

	Filename	Description	Size
	1-s2.0-S0009279720300041-main.pdf	Published version	954.34 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Gupta, G
dc.contributor.author	Dahiya, R
dc.contributor.author	Singh, Y
dc.contributor.author	Mishra, A
dc.contributor.author	Verma, A
dc.contributor.author	Gothwal, SK
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Dureja, H
dc.contributor.author	Prasher, P
dc.contributor.author	Negi, P
dc.contributor.author	Kapoor, DN
dc.contributor.author	Goyal, R
dc.contributor.author	Tambuwala, MM
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2020-08-24T06:09:53Z
dc.date.available	2020-02-03
dc.date.available	2020-08-24T06:09:53Z
dc.date.issued	2020-02-04
dc.identifier.citation	Chemico-biological interactions, 2020, 317
dc.identifier.issn	0009-2797
dc.identifier.issn	1872-7786
dc.identifier.uri	http://hdl.handle.net/10453/142329
dc.description.abstract	In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	ELSEVIER IRELAND LTD
dc.relation.ispartof	Chemico-biological interactions
dc.relation.isbasedon	10.1016/j.cbi.2020.108975
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology
dc.subject.classification	Toxicology
dc.subject.mesh	Humans
dc.subject.mesh	Kidney Diseases
dc.subject.mesh	Aldosterone
dc.subject.mesh	Adrenal Cortex Hormones
dc.subject.mesh	Angiotensin-Converting Enzyme Inhibitors
dc.subject.mesh	Renin-Angiotensin System
dc.subject.mesh	Angiotensin Receptor Antagonists
dc.subject.mesh	Humans
dc.subject.mesh	Kidney Diseases
dc.subject.mesh	Aldosterone
dc.subject.mesh	Adrenal Cortex Hormones
dc.subject.mesh	Angiotensin-Converting Enzyme Inhibitors
dc.subject.mesh	Renin-Angiotensin System
dc.subject.mesh	Angiotensin Receptor Antagonists
dc.subject.mesh	Adrenal Cortex Hormones
dc.subject.mesh	Aldosterone
dc.subject.mesh	Angiotensin Receptor Antagonists
dc.subject.mesh	Angiotensin-Converting Enzyme Inhibitors
dc.subject.mesh	Humans
dc.subject.mesh	Kidney Diseases
dc.subject.mesh	Renin-Angiotensin System
dc.title	Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.
dc.type	Journal Article
utslib.citation.volume	317
utslib.location.activity	Ireland
utslib.for	0601 Biochemistry and Cell Biology
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2020-08-24T06:09:44Z
pubs.publication-status	Published
pubs.volume	317

Abstract:

In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/142329